Kalligeros, Markos
Kröner, Paul T.
Farraye, Francis A.
Desalermos, Athanasios
Article History
Accepted: 1 January 2023
First Online: 24 January 2023
Declarations
:
: None. This study was retrospective review of publicly available database. No IRB approval or patient consent were obtained.
: M.K., P.T.K., and A.D. declare that they have no potential conflict of interest. F.A.F. is a consultant for BMS, Braintree labs, GSK, Innovation Pharmaceuticals, Iterative Scopes, Janssen, Pfizer, and Sebela and sits on a DSMB for Lilly and Theravance.